29 July 2024
EMA/315898/2024
EMEA/H/C/003958

Public statement

Pemetrexed Krka (Pemetrexed)

Withdrawal of the marketing authorisation in the European Union

On 28 June 2024, the European Commission withdrew the marketing authorisation for Pemetrexed Krka (Pemetrexed) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, KRKA, d.d., Novo mesto, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pemetrexed Krka was granted marketing authorisation in the EU on 22 May 2018 for treatment of malignant pleural mesothelioma and non-small cell lung cancer treatment of malignant pleural mesothelioma and non-small cell lung cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023. The product had not been marketed in the EU since 2022.

Pemetrexed Krka is a generic medicine of Alimta. There are other generic medicinal products of Alimta authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pemetrexed Krka will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union